Schiffer Charles A
Division of Hematology/Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI 48201, USA.
Semin Hematol. 2008 Jan;45(1):3-7. doi: 10.1053/j.seminhematol.2007.10.002.
The myelodysplastic syndromes (MDS) are a heterogeneous group of disorders with a wide range of clinical and pathologic manifestations. A number of prognostic and morphologic classifications have been developed that can be helpful in terms of defining the characteristics of populations of patients in clinical trials and longitudinal observational studies, and sometimes in allowing comparisons of the outcomes of different treatment approaches. They are less helpful in guiding treatment decisions in individual patients and, unfortunately, provide little insight into the poorly understood biology of MDS. The merits and limitations of these classification systems are discussed.
骨髓增生异常综合征（MDS）是一组具有广泛临床和病理表现的异质性疾病。已经制定了一些预后和形态学分类，这有助于界定临床试验和纵向观察研究中患者群体的特征，有时也有助于比较不同治疗方法的结果。它们在指导个体患者的治疗决策方面帮助较小，而且遗憾的是，对人们了解甚少的MDS生物学几乎没有提供深入见解。本文讨论了这些分类系统的优缺点。
